Immuno-Oncology | Specialty

Emerging Immunotherapy Options for Metastatic NSCLC

January 30th 2018

Immunotherapy with Antiangiogenics in NSCLC

January 30th 2018

Immunotherapy in Metastatic NSCLC

January 30th 2018

PD-L1 Testing in Metastatic NSCLC

January 30th 2018

Radiotherapy Strategies in Locally Advanced NSCLC

January 30th 2018

Evolving Strategies for Locally Advanced NSCLC

January 30th 2018

Practical Considerations for Immunotherapy in Stage 3 NSCLC

January 30th 2018

Patient Selection for Immunotherapy in NSCLC

January 30th 2018

PACIFIC Trial in Locally Advanced NSCLC

January 30th 2018

Maintenance/Consolidation Therapy in NSCLC

January 30th 2018

Chemoradiotherapy in Unresectable Locally Advanced NSCLC

January 30th 2018

Radiation Therapy in Stage 3 NSCLC

January 30th 2018

Locally Advanced NSCLC: Operable Setting

January 30th 2018

Multimodality Approaches to Locally Advanced NSCLC

January 30th 2018

Treatment of Locally Advanced NSCLC

January 30th 2018

Treatment of Early-Stage NSCLC

January 30th 2018

New Criteria Needed to Evaluate Immunotherapy Responses

January 28th 2018

Most patients who appear to progress after they begin receiving anticancer immunotherapy will never exhibit a response to therapy.

Advances and Research Needs in Lymphoma

January 26th 2018

Investigating CAR T-Cell Therapy in Lymphoma

January 26th 2018

Approval of Acalabrutinib in Mantle Cell Lymphoma

January 26th 2018